

## CellerateRX Surgical Powder, Hydrolyzed Collagen

October, 2023

### Device

CellerateRX Surgical Powder is a Type I bovine hydrolyzed collagen.<sup>1</sup> The indications according to the manufacturer are for the management of surgical, traumatic, partial and full thickness wounds, as well as first- and second-degree burns.<sup>1</sup> Suitable for the surgical environment, the product and packaging are sterile and available in 2 sizes.<sup>1</sup>

### Actions for Consideration

**Partner:** Identify wound care, burn, trauma physicians, surgeons, and nurses to participate in a discussion related to review of the product. Be sure to include the appropriate clinical and non-clinical value analysis team members. Reimbursement specialists may be particularly helpful within this category. Identify evidence related to specific products.

**Connect:** Given the large number of wound care products available and the cost associated with inventory management, a careful review of all products is helpful. Understanding specialties that utilize or request use of this type of product will be important in determining financial impact. Collecting and reviewing physician data including usage, cost, and waste will help inform management. Reimbursement information should be attained.

**Communicate:** Educate team on product details (indications, cost, and evidence) and physician requests or utilization. Review available evidence to develop a common goal. Discuss pricing, reimbursement, and potential to streamline products and develop strategies to manage use. Robust data sharing will not only enhance discussions, but may lead to actionable conversations between peers.

**HealthTrust Resources:** Access the [Clinical Knowledge Insights Library](#) to find other relevant documents and toolkits with actionable information. Examples for this category include resources on physician engagement and value analysis.<sup>2</sup> Network on [HealthTrust Huddle](#), our member community that shares ideas and seeks guidance from colleagues.<sup>3</sup>

### FDA Approval

CellerateRX was approved by the FDA under [K955506](#), submitted by The Hymed Group Corporation, (now part of SanaraMedTech) who distributes CellerateRX.<sup>4,5</sup>

### Physician Advisor Insight

A panel of general, trauma, and plastic surgeons within our HealthTrust Physician Advisor Network offered the following insight with regard to CellerateRX Surgical Powder<sup>7</sup>:

- Clinical acceptability is questionable without high quality studies and approval through a value analysis team may not be successful.
- There is no consistent data to support whether hydrolyzed or whole collagen would improve healing.
- A premium price is not warranted for this product, particularly in the absence of high-quality evidence.

## Summary

Addition of this type of product requires careful review by a multidisciplinary team to identify and understand potential utilization and cost impact, considering the lack of evidence. Ensuring physician partners are included in the discussion, as well as reimbursement specialists, will be particularly helpful in this space. Approval for use may be limited to very specific procedures. Therefore, implementation of a tracking process to monitor utilization would be beneficial.

## References

1. Sanara MedTech. CellerateRX Surgical Powder. <https://sanamedtech.com/surgical/celleraterx-surgical/>. Published 2023. Accessed October 13, 2023.
2. Healthtrust Purchasing Group. Clinical Knowledge Insights. Updated 2023. <http://www.hpginsights.com/>. Published 2023. Accessed October 13, 2023.
3. HealthTrust Purchasing Group. HealthTrust Huddle. Updated 2023. <https://huddle.healthtrustpg.com/forum/>. Published 2023. Accessed October 13, 2023.
4. United States Food and Drug Association. 510(k) Premarket Notification. Hycure. <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?id=K955506>. Accessed October 12, 2023.
5. Sanara MedTech. Sanara medtech inc. Announces the acquisition of certain assets related to its collagen products business. 2023. <https://sanamedtech.com/news/sanara-medtech-inc-announces-the-acquisition-of-certain-assets-related-to-its-collagen-products-business/>. Published 2023. Accessed October 22, 2023.
6. Mathew-Steiner SS, Roy S, Sen CK. Collagen in Wound Healing. *Bioengineering (Basel)*. 2021;8(5):63. Published 2021 May 11. doi:10.3390/bioengineering8050063.
7. 2023 Physician Advisor Network: General, Trauma, and Plastic Surgeon Survey. Collected September 28<sup>th</sup> through October 9<sup>th</sup>, 2023.